Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female
https://doi.org/10.4081/dr.2025.10278
Accepted: 15 February 2025
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
A 19-year-old female with severe hidradenitis suppurativa (HS), treated with adalimumab for 10 months, developed facial erysipelas following an episode of pharyngitis. The infection presented with fever, severe cough, and a rapidly progressing erythematous plaque with edema on the left cheek, forehead, and periocular region. Laboratory tests confirmed a streptococcal infection. Due to allergies and intolerance to first-line antibiotics, azithromycin was administered, leading to complete resolution. This case highlights the increased risk of severe infections in immunosuppressed patients and underscores the importance of careful antibiotic selection and close monitoring for infections in patients receiving TNF-α inhibitors.
Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol 2024. DOI: https://doi.org/10.1111/jdv.20472
Gambardella A, Calabrese G, Di Brizzi EV, et al. A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. J Eur Acad Dermatol Venereol 2020;34:e284-6. DOI: https://doi.org/10.1111/jdv.16280
Trelease-Bell A. Skin Infections and Outpatient Burn Management: Bacterial Skin Infections. FP Essent 2020;489:11-5.
Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clin Cosmet Investig Dermatol 2023;16:135-48. DOI: https://doi.org/10.2147/CCID.S391356
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol 2020;82:1061-82. DOI: https://doi.org/10.1016/j.jaad.2019.08.089
Zheng B, Liu M, Dai D, et al. Safety of TNF-α inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database. Medicine (Baltimore) 2024;103:e39012. DOI: https://doi.org/10.1097/MD.0000000000039012
Garbayo-Salmons P, Vilarrasa E, Bassas-Vila J, et al. Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2024. DOI: https://doi.org/10.1111/jdv.20044
Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol 2024;20:525-45. DOI: https://doi.org/10.1080/1744666X.2023.2298356
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
